Clinical Trial Update: Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of iparomlimab and tuvonralimab with chemotherapy to convert initially unresectable Stage III non-small cell lung can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Chang Chen | Conditions: NSCLC (Non-small-cell Lung Cancer) | Phase 2 | Status: NOT_YET_RECRUITING